Sign in →

Test ID PDGP Peroxisomal Disorder Gene Panel, Varies

Ordering Guidance

Preliminary biochemical testing may be helpful in making a diagnosis. Recommended first-tier biochemical testing for peroxisomal disorders analyzes very long-chain fatty acids; order POX / Fatty Acid Profile, Peroxisomal (C22-C26), Serum.


Customization of this panel and single gene analysis for any gene present on this panel is available. For more information see CGPH/ Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies. 

Shipping Instructions

Specimen preferred to arrive within 96 hours of collection.

Specimen Required

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.


Submit only 1 of the following specimens:


Specimen Type: Whole blood


Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot

Specimen Stability Information: Ambient (preferred)/Refrigerated


Specimen Type: Skin biopsy

Supplies: Fibroblast Biopsy Transport Media (T115)

Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.

Specimen Volume: 4-mm punch

Specimen Stability Information: Refrigerated (preferred)/Ambient

Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.


Specimen Type: Cultured fibroblast

Container/Tube: T-25 flask

Specimen Volume: 2 Flasks

Collection Instructions: Submit confluent cultured fibroblast cells from a skin biopsy from another laboratory. Cultured cells from a prenatal specimen will not be accepted.

Specimen Stability Information: Ambient (preferred)/Refrigerated (<24 hours)

Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.


Specimen Type: Blood spot

Supplies: Card-Blood Spot Collection (Filter Paper) (T493)


Preferred: Collection card (Whatman Protein Saver 903 Paper)

Acceptable: PerkinElmer 226 (formerly Ahlstrom 226) filter paper or blood spot collection card

Specimen Volume: 5 Blood spots

Collection Instructions:

1. An alternative blood collection option for a patient older than 1 year of age is finger stick. See Dried Blood Spot Collection Tutorial for how to collect blood spots via fingerstick.

2. Let blood dry on the filter paper at ambient temperature in a horizontal position for a minimum of 3 hours.

3. Do not expose specimen to heat or direct sunlight.

4. Do not stack wet specimens.

5. Keep specimen dry

Specimen Stability Information: Ambient (preferred)/Refrigerated

Additional Information:

1. Due to lower concentration of DNA yielded from blood spot, it is possible that additional specimen may be required to complete testing.

2. For collection instructions, see Blood Spot Collection Instructions

3. For collection instructions in Spanish, see Blood Spot Collection Card-Spanish Instructions (T777)

4. For collection instructions in Chinese, see Blood Spot Collection Card-Chinese Instructions (T800)


 Specimen Type: Saliva

Patient Preparation: Patient should not eat, drink, smoke, or chew gum 30 minutes prior to collection.

Supplies: Saliva Swab Collection Kit (T786)

Specimen Volume: 1 swab

Collection Instructions: Collect and send specimen per kit instructions.

Specimen Stability Information: Ambient 30 days

Additional Information: Due to lower concentration of DNA yielded from saliva, it is possible that additional specimen may be required to complete testing.


1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:

-Informed Consent for Genetic Testing  (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

2. Molecular Genetics: Biochemical Disorders Patient Information (T527) in Special Instructions

Useful For

Follow up of abnormal biochemical result, usually very long-chain fatty acid test consistent with peroxisomal disorder


Establishing a molecular diagnosis for patients with peroxisomal disorders


Identifying variants within genes known to be associated with peroxisomal disorders, allowing for predictive testing of at-risk family members

Testing Algorithm

See Newborn Screen Follow-up for X-Linked Adrenoleukodystrophy


For skin biopsy or cultured fibroblast specimens, fibroblast culture testing will be performed at an additional charge. If viable cells are not obtained, the client will be notified.

Method Name

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing.

Reporting Name

Peroxisomal Disorder Gene Panel

Specimen Type


Specimen Minimum Volume

See Specimen Required

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Clinical Information

Peroxisomes are responsible for catabolic actions of cells, including beta oxidation of very long-chain fatty acids, and anabolic actions, including biosynthesis of bile acids and plasmalogens. Peroxisomal disorders can be categorized into 2 major groups based on the function that is disrupted: peroxisomal biogenesis disorders and single peroxisomal enzyme deficiencies.


Peroxisomal biogenesis disorders are caused by defective assembly of the organelle resulting in some amount of deficient functional peroxisomes. Severity of disease is dependent on amount of remaining functional peroxisomes. Peroxisomal biogenesis disorders include those in the Zellweger spectrum: Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. Clinical features are usually progressive and include developmental delay, liver disease, blindness, and deafness. Severity is variable with Zellweger syndrome being the most severe and infantile Refsum disease being the least severe.


These are due to variants in the PEX genes that are responsible for encoding proteins for peroxisome assembly.


Peroxisomal enzyme deficiencies cause a disruption in peroxisomal function, although the organelles remain intact. The most common peroxisomal disorder, X-linked adrenoleukodystrophy, is an enzyme deficiency due to variants in the ABCD1 gene. Other enzyme deficiencies include rhizomelic chondrodysplasia type 2 and 3, and congenital bile acid synthesis defect.


This panel includes sequencing of 30 genes related to both peroxisomal biogenesis disorders and enzyme deficiencies. 

Reference Values

An interpretive report will be provided.


All detected alterations are evaluated according to American College of Medical Genetics and Genomics (ACMG) recommendations.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Clinical Reference

1. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424

2. Waterham, HR, Ebberink MS: Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim Biophys Acta. 2012;1822(9):1430-1441

3. Wanders RJ: Metabolic and molecular basis of peroxisomal disorders: a review. Am J Med Genet A. 2004;126A(4):355-375

4. Wanders RJ, Waterham HR: Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta. 2006;1763(12):1707-1720

5. Fidaleo M: Peroxisomes and peroxisomal disorders: the main facts. Exp Toxicol Pathol. 2010;62(6):615-625 

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information


88233-Tissue culture, skin, solid tissue biopsy (if appropriate)

88240-Cryopreservation (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PDGP Peroxisomal Disorder Gene Panel In Process


Result ID Test Result Name Result LOINC Value
608560 Test Description 62364-5
608561 Specimen 31208-2
608562 Source 31208-2
608563 Result Summary 50397-9
608564 Result 82939-0
608565 Interpretation 69047-9
608566 Resources 99622-3
608567 Additional Information 48767-8
608568 Method 85069-3
608569 Genes Analyzed 48018-6
608570 Disclaimer 62364-5
608571 Released By 18771-6

Day(s) Performed


Report Available

4 to 6 weeks

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
CULFB Fibroblast Culture for Genetic Test Yes No